The process of inflammation is a complex and necessary response to biological, chemical, or physical stimuli The cellular and molecular events that initiate and regulate the interactions between the various players in the inflammatory process remain a source of ongoing investigation. Chronic inflammation has been reported to contribute to numerous diseases, including arthritis, asthma, atherosclerosis, diabetes, cancer, and to conditions of aging.
It is important that research today focuses on looking at drug repurposing, in order to reduce the high attrition rates, substantial costs, and slow pace of new drug discovery and development. There are many pathways involved in the development of inflammation. Therefore, it is apparent that drugs already on the market for other therapeutic purposes, which are able to intervene in the processes of resolution of the inflammation, are possible candidates for reducing the impact and consequences of other disorders with the same common mechanisms. Repurposing drugs can be a challenge because it is not easy to find a candidate drug able to compete with the enormous amount of drugs commonly used in the clinical practice for the specific diseases in question. Therefore, a large amount of research is required to overcome this.
We welcome original research and review papers that demonstrate the strong crosstalk between inflammation and the improvement in the complication of the disease and a deeper understanding of the molecular mechanisms involved in the assessment of repurposed drugs. Furthermore, we invite authors to not neglect the aspects concerning possible adverse effects and pharmaceutical interactions of these repurposed drugs.
The process of inflammation is a complex and necessary response to biological, chemical, or physical stimuli The cellular and molecular events that initiate and regulate the interactions between the various players in the inflammatory process remain a source of ongoing investigation. Chronic inflammation has been reported to contribute to numerous diseases, including arthritis, asthma, atherosclerosis, diabetes, cancer, and to conditions of aging.
It is important that research today focuses on looking at drug repurposing, in order to reduce the high attrition rates, substantial costs, and slow pace of new drug discovery and development. There are many pathways involved in the development of inflammation. Therefore, it is apparent that drugs already on the market for other therapeutic purposes, which are able to intervene in the processes of resolution of the inflammation, are possible candidates for reducing the impact and consequences of other disorders with the same common mechanisms. Repurposing drugs can be a challenge because it is not easy to find a candidate drug able to compete with the enormous amount of drugs commonly used in the clinical practice for the specific diseases in question. Therefore, a large amount of research is required to overcome this.
We welcome original research and review papers that demonstrate the strong crosstalk between inflammation and the improvement in the complication of the disease and a deeper understanding of the molecular mechanisms involved in the assessment of repurposed drugs. Furthermore, we invite authors to not neglect the aspects concerning possible adverse effects and pharmaceutical interactions of these repurposed drugs.
